Gain Therapeutics | 8-K: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.15.

EBIT: As of FY2025 Q3, the actual value is USD -4.864 M.

Financial Metrics Summary

Research and Development (R&D) Expenses

• R&D expenses increased by $0.2 million to $2.8 million for the three months ended September 30, 2025, compared to $2.6 million for the same period in 2024. This increase was primarily due to costs associated with the ongoing Phase 1b clinical trial and unfavorable foreign exchange currency translation.

General and Administrative (G&A) Expenses

• G&A expenses increased by $0.1 million to $1.9 million for the three months ended September 30, 2025, compared to $1.8 million for the same period in 2024. The increase was mainly due to higher stock-based compensation and personnel costs, partially offset by lower legal and professional fees.

Net Loss

• Net loss for the three months ended September 30, 2025, was $0.15 per share, basic and diluted, compared to $0.17 per share for the same period in 2024.

Cash and Cash Equivalents

• Cash and cash equivalents were $8.8 million as of September 30, 2025, compared to $10.4 million as of December 31, 2024.

Outlook / Guidance

• Gain Therapeutics expects to report the analysis of functional changes and biomarker activity during the fourth quarter of 2025. The company plans to submit an IND to the FDA by the end of 2025 to facilitate expansion into Phase 2 clinical development of GT-02287. Results from the Phase 1b study extension are anticipated in the second half of 2026.